Low-density lipoprotein cholesterol lowering treatment: the current approach. 2020

Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
Emergency Institute for Cardiovascular Diseases "C.C. Iliescu", Bucharest, Romania.

In the last 50 years, several clinical and epidemiological studies during have shown that increased levels of low-density lipoprotein cholesterol (LDLc) are associated with the development and progression of atherosclerotic lesions. The discovery of β-Hydroxy β-methylglutaryl-CoA reductase inhibitors (statins), that possess LDLc-lowering effects, lead to a true revolution in the prevention and treatment of cardiovascular diseases. Statins remain the cornerstone of LDLc-lowering therapy. Lipid-lowering drugs, such as ezetimibe and bile acid sequestrants, are prescribed either in combination with statins or in monotherapy (in the setting of statin intolerance or contraindications to statins). Microsomal triglyceride transfer protein inhibitors and protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are other drug classes which have been investigated for their potential to decrease LDLc. PCSK9 have been approved for the treatment of hypercholesterolemia and for the secondary prevention of cardiovascular events. The present narrative review discusses the latest (2019) guidelines of the European Atherosclerosis Society/European Society of Cardiology for the management of dyslipidemia, focusing on LDLc-lowering drugs that are either already available on the market or under development. We also consider "whom, when and how" do we treat in terms of LDLc reduction in the daily clinical practice.

UI MeSH Term Description Entries
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D003998 Dicarboxylic Acids Acyclic acids that contain two carboxyl groups and have the formula HO2C-R-CO2H, where R may be an aromatic or aliphatic group. Acids, Dicarboxylic
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D005227 Fatty Acids Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed) Aliphatic Acid,Esterified Fatty Acid,Fatty Acid,Fatty Acids, Esterified,Fatty Acids, Saturated,Saturated Fatty Acid,Aliphatic Acids,Acid, Aliphatic,Acid, Esterified Fatty,Acid, Saturated Fatty,Esterified Fatty Acids,Fatty Acid, Esterified,Fatty Acid, Saturated,Saturated Fatty Acids
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006937 Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population. Hypercholesteremia,Elevated Cholesterol,High Cholesterol Levels,Cholesterol Level, High,Cholesterol Levels, High,Cholesterol, Elevated,Cholesterols, Elevated,Elevated Cholesterols,High Cholesterol Level,Hypercholesteremias,Hypercholesterolemias,Level, High Cholesterol,Levels, High Cholesterol
D000069438 Ezetimibe An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS. (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone),Ezetimib,Ezetrol,SCH 58235,SCH-58235,SCH58235,Zetia,58235, SCH
D000071449 Proprotein Convertase 9 A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS. NARC-1 Protein,Neural Apoptosis-Regulated Convertase 1,Proprotein Convertase, Subtilisin-Kexin Type 9,Convertase 9, Proprotein,NARC 1 Protein,Neural Apoptosis Regulated Convertase 1,Proprotein Convertase, Subtilisin Kexin Type 9
D000091362 PCSK9 Inhibitors Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level. PCSK9 Inhibitors Cardiovascular,PCSK9 Inhibitors, Cardiovascular,Cardiovascular PCSK9 Inhibitors,Cardiovascular, PCSK9 Inhibitors,Inhibitors, Cardiovascular PCSK9

Related Publications

Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
January 2019, Future cardiology,
Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
June 2000, International journal of clinical practice,
Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
January 2021, Frontiers in cardiovascular medicine,
Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
July 2012, Pharmacology & therapeutics,
Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
January 2012, Circulation journal : official journal of the Japanese Circulation Society,
Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
February 2024, Journal of clinical medicine,
Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
December 2020, European heart journal. Acute cardiovascular care,
Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
November 2022, Cardiovascular research,
Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
November 2000, The American journal of managed care,
Irina Crismaru, and Anca Pantea Stoian, and Ovidiu Gabriel Bratu, and Mihnea-Alexandru Gaman, and Ana Maria Alexandra Stanescu, and Nicolae Bacalbasa, and Camelia Cristina Diaconu
June 2010, Journal of the American College of Cardiology,
Copied contents to your clipboard!